MGMichael Ghadimi

Michael Ghadimi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael Ghadimi has a total of 231 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Editorial

    by Michael Ghadimi

    Liebe Kolleginnen und Kollegen, ein Schwerpunktheft aus dem Bereich Trauma im Zentralblatt für Chirurgie ist überfällig und hochaktuell. Zum einen ändert sich auch im Bereich der Traumaversorgung in Deutschland vieles aufgrund der angespannten Situation in den Kliniken, aber noch mehr infolge der notwendigen Spezialisierungen und Zentralisierungen in den Traumanetzwerken. Zum anderen sind wir mit kriegerischen Auseinandersetzungen in Europa konfrontiert und auch in Deutschland sind viele schwerverletzte ukrainische Soldaten behandelt worden. Der speziellen Situation von Schwerstverletzten in Kriegen widmet sich der Artikel von Franke et al. [1] aus den Bundeswehrkrankenhäusern Koblenz und Ulm. Hier werden die Unterschiede und die Spezifika in der Versorgung von Schwerstverletzten in zivilen Situationen und im Krieg beleuchtet. Es werden die Algorithmen der Bundeswehr sowie in den Konzepten der NATO thematisiert und es fließen Erfahrungen der Bundeswehr aus den Einsätzen in Afghanistan ein. Aufgrund der aktuellen Situation in der Ukraine hatte das Bundesverteidigungsministerium die Deutsche Gesellschaft für Unfallchirurgie (DGU) damit beauftragt, in ihrem TraumaNetzwerk im Kleeblattprinzip die Verteilung von schwerverletzten ukrainischen Soldaten zu organisieren. Die Versorgung von Schwerverletzten betrifft verschiedene Organsysteme und bedarf hochprofessioneller Teamstrukturen, um eine hohe Ergebnisqualität zu gewährleisten. Vital kritische Organsysteme bzw. anatomische Kompartimente stellen hier besonders der Thorax und das Abdomen dar. Für das häufig lebensbedrohliche abdominelle Trauma haben Schild-Suhrens et al. [2] eine Übersicht geschaffen, die die wesentlichen Organverletzungen von Leber, Milz, Pankreas und auch der Niere beleuchtet. Unter Beteiligung sehr sachverständiger interventioneller Radiologen werden mögliche nicht operative Techniken diskutiert, die in jedem erfahrenen großen Traumazentrum 24/7 vorhanden sein müssen. Bei Schwerverletzten liegt laut TraumaRegister DGU bei 50% der Patientinnen und Patienten ein Thoraxtrauma vor. Spering et al. [3] haben sich sehr detailliert dem Management des Thoraxtraumas gewidmet, das sehr häufig eine Priorisierung im Schockraum erhält und glücklicherweise zügig durch die Anlage von Thoraxdrainagen oder minimalinvasiven OP-Techniken zu therapieren ist. Eine relevante Frage bleibt nach der häufigsten Todesursache von Schwerverletzten: Woran verstirbt der schwerverletzte Patient? Der Herausgeber ist Lefering et al. [4] sehr dankbar, die hochinteressanten Daten aus 30 Jahren TraumaRegister DGU für dieses Schwerpunktheft aufgearbeitet zu haben. Es zeigt sich hier, dass mit zunehmendem zeitlichem Abstand vom Trauma schnell die Letalität sinkt und das Schädel-Hirn-Trauma die dominante Todesursache darstellt. Wolfgang Lehmann [5] aus Göttingen skizziert in seinem Artikel die Zukunft der Traumaversorgung in Deutschland. Er erarbeitet die aktuellen Probleme der zunehmenden Fallzahlen bei reduzierten Bettenkapazitäten, die langfristig Sorgen bereiten können. Dieses berufspolitisch überaus wichtige Thema muss jetzt diskutiert und angegangen werden. Hierzu ist die Beteiligung aller Stakeholder zwingend notwendig, um langfristig belastbare Strukturen zu schaffen, die eine hohe Ergebnisqualität gewährleisten. Ich hoffe, dass Ihnen die Lektüre dieses Schwerpunktheftes Freude bereitet und Einblicke in die Traumaversorgung gibt. Wir Allgemein-, Viszeral-, Thorax und Gefäßchirurgen sind häufig im Schockraum und auf den Intensivstationen gemeinsam mit unseren Kolleginnen und Kollegen der Unfallchirurgie in der Behandlung von Schwerverletzten vereint. Mit besten Grüßen aus Göttingen Michael Ghadimi Article published online: 07 August 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Open Access

    Short- and Long-Term Outcomes of Patients with Postoperative Arrhythmia after Liver Surgery

    by Felix Rühlmann, Deborah Engelhardt, Alma Franziska Mackert, Mara Sophie Hedicke, Tobias Tichelbäcker, Andreas Leha, Markus Bernhardt, Michael Ghadimi, Thorsten Perl, Azadeh Azizian, et al.

    Background: New-onset postoperative arrhythmia (PA) has previously been described as a pivotal risk factor for postoperative morbidity and mortality after visceral surgery. However, there is a lack of data concerning liver surgery. The incidence and impact of new-onset postoperative arrhythmia after liver surgery was, therefore, analyzed in a monocentric study. Methods: In total, n = 460 patients (221 female, 239 male) who underwent liver surgery between January 2012 and April 2020 without any prior arrhythmia in their medical history were included in this retrospective analysis. Clinical monitoring started with the induction of anesthesia and was terminated with discharge from the intensive care unit (ICU) or intermediate care unit (IMC). Follow-up included documentation of complications during the hospital stay, as well as long-term survival analysis. Results: Postoperative arrhythmia after liver surgery was observed in 25 patients, corresponding to an incidence of 5.4%. The occurrence of arrhythmia was significantly associated with intraoperative complications (p < 0.05), liver fibrosis/cirrhosis (p < 0.05), bile fistula/bile leakage/bilioma (p < 0.05), and organ failure (p < 0.01). Survival analysis showed a significantly poorer overall survival of patients who developed postoperative arrhythmia after liver surgery (p < 0.001). Conclusions: New-onset postoperative arrhythmia after liver surgery has an incidence of only 5.4% but is significantly associated with higher postoperative morbidity and poorer overall survival.

  • Open Access

    Perioperative LiMAx Test Analysis: Impact of Portal Vein Embolisation, Chemotherapy and Major Liver Resection

    by Felix Rühlmann, Azadeh Azizian, Christian Moosmann, Markus Bernhardt, Jan Keck, Hannah Flebbe, Omar Al-Bourini, Ali Seif Amir Hosseini, Marian Grade, Thomas Lorf, et al.

    Background: Postoperative liver failure (PLF) is a severe complication after major liver resection (MLR). To increase the safety of patients, clinical bedside tests are of great importance. However, limitations of their applicability and validity impair their value. Methods: Preoperative measurements of the liver maximum capacity (LiMAx) were performed in n = 40 patients, who underwent MLR (≥3 segments). Matched postoperative LiMAx was measured in n = 21 patients. Liver function was compared between pretreated patients (n = 11 with portal vein embolisation (PVE) and n = 19 patients with preoperative chemotherapy) and therapy naïve patients. The LiMAx values were compared with liver-specific blood parameters and volumetric analysis. Results: In total, n = 40 patients were enrolled in this study. The majority of patients (n = 33; 82.5%) had high preoperative LiMAx values (>315 µg/kg/h), while only seven patients (17.5%) had medium values (140–315 µg/kg/h), and none of the patients had low values ( 0.05). The preoperative LiMAx values were significantly higher than the matched postoperative values on postoperative day 1 (p < 0.0001). A comparison between the expected and measured postoperative LiMAx showed a difference (≥10%) in 7 out of 13 patients (53.8%). After an initial postoperative decrease in the LiMAx, the patients without complications (n = 12) showed a continuous increase until 14 days after surgery. In the patients with postoperative complications, a decrease in the LiMAx was associated with a prolonged recovery. Conclusions: For patients undergoing MLR within the 0.5% rule, which is the clinical gold standard, the LiMAx values do not offer any additional information. Additionally, the LiMAx may have reflected liver function, but it did not deliver additional information regarding postoperative liver recovery. The clinical use of LiMAx might be relevant in selected patients beyond the 0.5% rule.


  • Open Access

    Consensus Statement on the Use of Near-Infrared Fluorescence Imaging during Pancreatic Cancer Surgery Based on a Delphi Study: Surgeons’ Perspectives on Current Use and Future Recommendations

    by Lysanne D. A. N. de Muynck, Kevin P. White, Adnan Alseidi, Elisa Bannone, Luigi Boni, Michael Bouvet, Massimo Falconi, Hans F. Fuchs, Michael Ghadimi, Ines Gockel, et al.

    Indocyanine green (ICG) is one of the only clinically approved near-infrared (NIR) fluorophores used during fluorescence-guided surgery (FGS), but it lacks tumor specificity for pancreatic ductal adenocarcinoma (PDAC). Several tumor-targeted fluorescent probes have been evaluated in PDAC patients, yet no uniformity or consensus exists among the surgical community on the current and future needs of FGS during PDAC surgery. In this first-published consensus report on FGS for PDAC, expert opinions were gathered on current use and future recommendations from surgeons’ perspectives. A Delphi survey was conducted among international FGS experts via Google Forms. Experts were asked to anonymously vote on 76 statements, with ≥70% agreement considered consensus and ≥80% participation/statement considered vote robustness. Consensus was reached for 61/76 statements. All statements were considered robust. All experts agreed that FGS is safe with few drawbacks during PDAC surgery, but that it should not yet be implemented routinely for tumor identification due to a lack of PDAC-specific NIR tracers and insufficient evidence proving FGS’s benefit over standard methods. However, aside from tumor imaging, surgeons suggest they would benefit from visualizing vasculature and surrounding anatomy with ICG during PDAC surgery. Future research could also benefit from identifying neuroendocrine tumors. More research focusing on standardization and combining tumor identification and vital-structure imaging would greatly improve FGS’s use during PDAC surgery.


  • Schnittstellen zwischen Innovation und Versorgung

    by Michael Ghadimi

  • Open Access

    Pelvic Intraoperative Neuromonitoring Prevents Dysfunction in Patients With Rectal Cancer

    by Werner Kneist, Michael Ghadimi, Norbert Runkel, Thomas Moesta, Stephan Coerper, Claudia Benecke, Daniel W. Kauff, Stephan Gretschel, Ines Gockel, Boris Jansen-Winkeln, et al.

    Objective: This NEUROmonitoring System (NEUROS) trial assessed whether pelvic intraoperative neuromonitoring (pIONM) could improve urogenital and ano-(neo-)rectal functional outcomes in patients who underwent total mesorectal excisions (TMEs) for rectal cancer. Background: High-level evidence from clinical trials is required to clarify the benefits of pIONM. Methods: NEUROS was a 2-arm, randomized, controlled, multicenter clinical trial that included 189 patients with rectal cancer who underwent TMEs at 8 centers, from February 2013 to January 2017. TMEs were performed with pIONM (n=90) or without it (control, n=99). The groups were stratified according to neoadjuvant chemoradiotherapy and sex, with blocks of variable length. Data were analyzed according to a modified intention-to-treat protocol. The primary endpoint was a urinary function at 12 months after surgery, assessed with the International Prostate Symptom Score, a patient-reported outcome measure. Deterioration was defined as an increase of at least 5 points from the preoperative score. Secondary endpoints were sexual and anorectal functional outcomes, safety, and TME quality. Results: The intention-to-treat analysis included 171 patients. Marked urinary deterioration occurred in 22/171 (13%) patients, with significantly different incidence between groups (pIONM: n=6/82, 8%; control: n=16/89, 19%; 95% confidence interval, 12.4–94.4; P=0.0382). pIONM was associated with better sexual and ano-(neo)rectal function. At least 1 serious adverse event occurred in 36/88 (41%) in the pIONM group and 53/99 (54%) in the control group, none associated with the study treatment. The groups had similar TME quality, surgery times, intraoperative complication incidence, and postoperative mortality. Conclusion: pIONM is safe and has the potential to improve functional outcomes in rectal cancer patients undergoing TME.


  • Open Access

    Comparing Apparent Diffusion Coefficient and FNCLCC Grading to Improve Pretreatment Grading of Soft Tissue Sarcoma—A Translational Feasibility Study on Fusion Imaging

    by Madelaine Hettler, Julia Kitz, Ali Seif Amir Hosseini, Manuel Guhlich, Babak Panahi, Jennifer Ernst, Lena-Christin Conradi, Michael Ghadimi, Philipp Ströbel, Jens Jakob

    Histological subtype and grading are cornerstones of treatment decisions in soft tissue sarcoma (STS). Due to intratumoral heterogeneity, pretreatment grading assessment is frequently unreliable and may be improved through functional imaging. In this pilot study, 12 patients with histologically confirmed STS were included. Preoperative functional magnetic resonance imaging was fused with a computed tomography scan of the resected specimen after collecting core needle biopsies and placing radiopaque markers at distinct tumor sites. The Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) grading criteria of the biopsies and apparent diffusion coefficients (ADCs) of the biopsy sites were correlated. Concordance in grading between the specimen and at least one biopsy was achieved in 9 of 11 cases (81.8%). In 7 of 12 cases, fusion imaging was feasible without relevant contour deviation. Functional analysis revealed a tendency for high-grade regions (Grade 2/3 (G2/G3)) (median (range) ± standard deviation: 1.13 (0.78–1.70) ± 0.23 × 10−3 mm2/s) to have lower ADC values than low-grade regions (G1; 1.43 (0.64–2.03) ± 0.46 × 10−3 mm2/s). In addition, FNCLCC scoring of multiple tumor biopsies proved intratumoral heterogeneity as expected. The ADC appears to correlate with the FNCLCC grading criteria. Further studies are needed to determine whether functional imaging may supplement histopathological grading.


  • Rectal Cancer: Open Questions in 2022 Current Standards of Clinical Practice and Ongoing Trials

    by Lena-Christin Conradi, Claus Rödel, Michael Ghadimi

    Background: Rectal cancer remains a complex disease and a relevant global health issue, increasingly affecting also younger patients. This update review summarizes the current standard of care and discusses the individualized treatment approaches taking into consideration individual tumor characteristics and patients preferences. Summary: Remaining “gray zones” of rectal cancer therapy warranting further prospective studies are identified including surgical approaches for rectal cancer, e.g., minimally invasive surgical techniques and lateral lymph node dissection for low rectal cancers. The emerging concept of a watch-and-wait strategy upon clinical complete response after chemoradiotherapy is discussed, also considering the still limited evidence and the clinical challenges arising from individualized patient management. Key Messages: Finally, currently conducted clinical trials of the German Rectal Cancer Study Group are described, aiming to further individualize multimodal treatment according to risk profiles and strict MRI criteria.